Press Releases
Microbiotica Announces Positive Results from its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma
18 May 2026/by Leyla KarabekmezMicrobiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
11 February 2026/by Leyla KarabekmezMicrobiotica Announces Completion of Recruitment in its International Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma
17 September 2025/by Leyla KarabekmezMicrobiotica Announces Completion of Recruitment in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients
4 August 2025/by Leyla KarabekmezMicrobiotica announces the appointment of Dr Robert Tansley as Chief Medical Officer
10 June 2025/by Leyla KarabekmezMicrobiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier
6 May 2025/by Leyla KarabekmezMicrobiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma
29 April 2025/by Leyla KarabekmezMicrobiotica presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma
26 February 2025/by Leyla KarabekmezMicrobiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis
21 February 2025/by Leyla Karabekmez
